Overview
Adstiladrin is approved by the U.S. Food and Drug Administration (FDA) to treat adults with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). This includes…

Overview
Anktiva is approved by the U.S. Food and Drug Administration (FDA) along with Bacillus Calmette-Guérin (BCG) to treat adults with a type of bladder cancer called BCG-unresponsive nonmuscle invasive bladder cancer…

Overview
Balversa is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with locally advanced or metastatic urothelial carcinoma (a type of bladder cancer) with specific fibroblast growth…

Overview
Bavencio is approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of locally advanced or metastatic urothelial carcinoma (a type of bladder cancer) that has not progressed with…

Overview
Imfinzi is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with muscle-invasive bladder cancer (MIBC) in combination with chemotherapy prior to surgery (neoadjuvant), followed…

Overview
Inlexzo is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ…

Overview

Keytruda is approved by the U.S. Food and Drug Administration (FDA) to treat certain types of bladder cancer. It is prescribed to treat advanced or metastatic (spreading) urothelial cancer, nonmuscle invasive…

Overview
Keytruda Qlex is approved by the U.S. Food and Drug Administration (FDA) to treat several forms of bladder cancer, which is the most common type of urothelial cancer. It is approved in combination with enfortumab…